A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2001
10/25/2001	WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	WO2001079158A2 Compounds for modulating cell proliferation
10/25/2001	WO2001079157A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001079153A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
10/25/2001	WO2001078757A2 Reversible immortalization
10/25/2001	WO2001078756A2 Agent for postoperative use after the removal of bone tumours
10/25/2001	WO2001078733A1 Alpha,beta-unsaturated sulfones for treating proliferative disorders
10/25/2001	WO2001078723A1 Compounds and methods
10/25/2001	WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078702A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001	WO2001078701A2 Method and compositions for preventing hormone induced adverse effects
10/25/2001	WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078533A2 Nutritional modules
10/25/2001	WO2001049288A9 Novel compounds and compositions as protease inhibitors
10/25/2001	WO2001039786A3 New uses of suppressive macrophage activation factors
10/25/2001	WO2001028987A8 Benzylcycloalkyl amines as modulators of chemokine receptor activity
10/25/2001	WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001	WO2001022092A3 Method to identify compounds which modulate fra-1 expression fils
10/25/2001	WO2001021643A3 Parathyroid hormone analogues for the treatment of osteoporosis
10/25/2001	WO2001021605A3 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
10/25/2001	WO2001012790A3 Isomerase proteins
10/25/2001	WO2000061541A8 Pharmaceutical compounds
10/25/2001	US20010034364 Isoprenoid pathway inhibitors for stimulating bone growth
10/25/2001	US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001	US20010034340 Hormone replacement therapy
10/25/2001	US20010034337 Antiproliferative agents
10/25/2001	US20010034334 Genetic engineered polypeptide
10/25/2001	US20010034331 Isolated polypeptide
10/25/2001	DE10020517A1 New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	DE10020125A1 Agent for stimulating bone regrowth, useful as insert after surgery for bone cancer, comprises single sequence expressing a fusion of growth factor and protease inhibitor
10/25/2001	DE10019195A1 Gene complex for reversible cell immortalization, useful for expanding cells for cell replacement therapy of e.g. neurodegenerative disease, contains removable immortalizing gene
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2406590A1 Agent for postoperative use after the removal of bone tumours
10/25/2001	CA2406442A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406192A1 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001	CA2406171A1 Reversible immortalization of cells
10/25/2001	CA2406160A1 Compounds for modulating cell proliferation
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2405451A1 Molecules associated with human reproduction
10/25/2001	CA2405377A1 Nutritional modules
10/25/2001	CA2404097A1 Method and compositions for preventing hormone induced adverse effects
10/25/2001	CA2403508A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001	CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	CA2376882A1 Novel recombinant antibody, amino acid sequences of its complementarity determining regions and genes encoding the same
10/24/2001	EP1148054A1 Thyroid receptor ligands
10/24/2001	EP1147776A2 Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
10/24/2001	EP1147775A2 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder
10/24/2001	EP1147773A1 Medicinal compositions for treating osseous lesion in multiple myeloma
10/24/2001	EP1147413A2 Growth differentiation factor inhibitors and uses therefor
10/24/2001	EP1147223A1 Identifying, monitoring, and treating women for breast precancer or cancer
10/24/2001	EP1147214A1 A novel method for designing protein kinase inhibitors
10/24/2001	EP1147202A2 Plasminogen kringle 4 region fragments and methods of use
10/24/2001	EP1147138A1 Hydrophilic ampholytic polymer
10/24/2001	EP1147133A2 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
10/24/2001	EP1147119A1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
10/24/2001	EP1147116A1 Boron steroid mimics and pharmaceutical compositions
10/24/2001	EP1147104A1 Aromatic heterocyclic compounds as antiinflammatory agents
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147101A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
10/24/2001	EP1147097A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147092A1 Substituted imidazoles, their preparation and use
10/24/2001	EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/24/2001	EP1147089A1 Phenylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147085A1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
10/24/2001	EP1147080A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
10/24/2001	EP1147079A2 Beta-phenylalanine derivatives as integrin antagonists
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146902A1 Treatment of autommune diseases by an agonistic cd40-binding protein
10/24/2001	EP1146897A1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair
10/24/2001	EP1146894A1 Uses of thank, a tnf homologue that activates apoptosis
10/24/2001	EP1146888A2 Specific therapeutic interventions obtained by interference with redistribution and/or targetting
10/24/2001	EP1146883A1 Modulation of immune response by ribavirin
10/24/2001	EP1146874A1 Vitronectin receptor antagonist
10/24/2001	EP1146870A1 Antioxidant compositions and methods for companion animals
10/24/2001	EP1146868A1 Anti-inflammatory agents
10/24/2001	EP1146790A1 Compounds and methods
10/24/2001	EP1146787A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
10/24/2001	EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
10/24/2001	CN1319139A Polynucleotide constructs and uses thereof
10/24/2001	CN1319131A Method and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
10/24/2001	CN1319097A Benzoxazine and benzothiazine derivatives and their use in medicines
10/24/2001	CN1319096A Quinazoline derivatives and pharmaceutical applications thereof
10/24/2001	CN1319093A Aminoalkyl-3,4-dihydroquindine derivates as No-synthase inhibitors
10/24/2001	CN1319092A Benzamide derivatives and their use as cytokine inhibitors
10/24/2001	CN1319017A Insertion stabilizers for implants
10/24/2001	CN1319016A Process for preparation of oral pharmaceutical compositions comprising biphosphonates
10/24/2001	CN1319015A Compositions containing diphosphonic acids
10/24/2001	CN1319008A Hydroxamate-containing cysteine and serine protease inhibitors
10/24/2001	CN1319003A Protein formulations
10/24/2001	CN1318408A External-use medicine for treating sore ulcer, wound, rheumatism and other diseases and its preparation

1 ... 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 ... 820